患有甲醇毒性的患者同时患有甲状腺功能障碍和威尔逊病:一个罕见的病例报告
Fatemeh Mohammadzadeh1, Alireza Fatemi2, Yasmin Yazdooei2
1Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Golestan, Iran.
Clinical medicine insights. Endocrinology and diabetes
|September 19, 2025
概括
本报告详细介绍了威尔逊病 (WD) 与甲状腺上下腺功能障碍和甲醇毒性同时发生的独特病例. 这种罕见的三位一体给临床医生带来了复杂的诊断和管理挑战.
科学领域:
- 内分泌学 在内分泌学.
- 毒理学 毒理学 毒理学
- 遗传学 是一个遗传学.
背景情况:
- 威尔逊病 (WD) 是一种铜代谢的遗传性疾病.
- 甲状腺功能障碍症是一种不常见的内分泌并发症,WD.
- 甲醇毒性是一种罕见但严重的疾病,很少见于WD和甲状腺功能障碍症.
研究的目的:
- 报告一个独特的病例,患者呈现了罕见的威尔逊病,甲状腺功能障碍和甲醇毒性三位一体.
- 突出这一复杂的临床表现所带来的诊断和治疗挑战.
主要方法:
- 一个案例介绍,一个53岁的男性患有未经治疗的WD.
- 临床检查显示了视神经病变.
- 实验室调查证实过血症和副甲状腺激素 (PTH) 的升高,表明过多甲状腺功能症. 对甲醇毒性开始进行透析.
主要成果:
- 患者出现了甲醇毒性的症状,包括恶心,吐,头和视力模糊.
- 一个患有威尔逊病的患者的甲状腺功能障碍的确诊.
- 通过透析和代谢酸性纠正成功管理甲醇毒性.
结论:
- 这一案例凸显了威尔逊病,甲状腺功能障碍和甲醇毒性的罕见共存.
- 这些疾病之间的病理生理相互作用需要进一步研究.
- 更好的理解可能会导致更好的管理策略和更好的临床结果.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Chronic Kidney Disease II: Clinical Manifestations
557
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
557
Toxic Reactions: Overview
1.8K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.8K
Anticholinesterase Agents: Poisoning and Treatment
1.5K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
215
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
215
Chronic Pancreatitis II: Collaborative Care
315
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
315


